Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy.

ABSTRACT:

Purpose

In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [¹⁶⁶Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT). The aim of this study was to analyze hematotoxicity profiles, (i.e. lymphocyte and neutrophile toxicity) and the prognostic value of neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR).

Methods

All patients included in the prospective HEPAR PLuS study were included in this study. Blood testing was performed at baseline (before radioembolization) and at regular intervals during 1-year follow-up. Radiological response was assessed at 3, 6, 9, and 12 months according to RECIST 1.1. Logistic regression was used to analyze the progn

SUBMITTER: Ebbers SC 

PROVIDER: S-EPMC8811020 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature